Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A. NP5.DE Peers
See (NP5.DE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
---|---|---|---|---|---|---|
NP5.DE | €7.86 | -0.88% | 156.9M | 9.25 | €0.85 | N/A |
NOVC.DE | €91.40 | -1.98% | 406.7B | 22.91 | €3.99 | N/A |
4AB.DU | €164.00 | -0.49% | 289.7B | N/A | N/A | +3.22% |
W8A.DE | €9.85 | -0.11% | 8.5B | -1.69 | -€5.84 | +5.81% |
RDC.DE | €98.55 | -1.35% | 2B | -40.89 | -€2.41 | N/A |
SAE.DE | €88.30 | N/A | 1.6B | -26.60 | -€3.32 | N/A |
2LYA.F | €2.04 | +0.74% | 165.1M | -40.80 | -€0.05 | N/A |
5EA.DE | €19.20 | N/A | 0 | N/A | N/A | N/A |
Stock Comparison
NP5.DE vs NOVC.DE Comparison
NP5.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NP5.DE stands at 156.9M. In comparison, NOVC.DE has a market cap of 406.7B. Regarding current trading prices, NP5.DE is priced at €7.86, while NOVC.DE trades at €91.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NP5.DE currently has a P/E ratio of 9.25, whereas NOVC.DE's P/E ratio is 22.91. In terms of profitability, NP5.DE's ROE is -1.09%, compared to NOVC.DE's ROE of +0.86%. Regarding short-term risk, NP5.DE is less volatile compared to NOVC.DE. This indicates potentially lower risk in terms of short-term price fluctuations for NP5.DE.